Library

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • 1995-1999  (3)
  • 1998  (1)
  • 1997  (2)
Source
Material
Years
  • 1995-1999  (3)
Year
Keywords
  • 1
    Electronic Resource
    Electronic Resource
    The expression of murine eutaneous late phase reaction requires both IgE antibodies and CD4 T eells (1997)
    Oxford, UK : Blackwell Publishing Ltd
    Clinical & experimental allergy 27 (1997), S. 0 
    Details
    ISSN: 1365-2222
    Source: Blackwell Publishing Journal Backfiles 1879-2005
    Topics: Medicine
    Notes: Background Exposure of atopic patients to a specific allergen evokes an immediate response which is followed, in many cases, by a late phase reaction (LPR) some hours later. Here we have examined the immunological mechanisms required for the expression of cutaneous LPR in mice.Methods BALB/c mice were immunized by i.p. injection of ovalbumin (OVA) and alum actively or by i.v. injection of anti-OVA IgE monoclonal antibody (mAb) passively. After challenge by intradermal injection of OVA into ears, the changes in ear thickness, the number of eosinophils, and the levels of IL4 and IFN-γ protein at the site of antigen challenge were examined.Results Actively immunized mice developed a biphasic response at the site of OVA injection, while mice passively immunized with IgE anti-OVA mAb displayed a strong early response but no LPR. Cell transfer experiments using BALB/c nu/nu mice revealed that both OVA-specific IgE mAb and OVA-primed CD4 T cells were required to evoke LPR. Moreover, LPR was associated with increased levels of IL-4 production concomitant with reduced IFN-γ production and was abolished by pretreatment with anti-IL-4 neutralizing mAb.Conclusion It is suggested that murine cutaneous LPR against OVA is a type 2 inflammatory response in which both IgH antibodies and CD4 T cells play an obligatory role.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1111/j.1365-2222.1997.tb00697.x
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    2-Oxo-1,2-dihydropyridine-6-carboxylic Acid (1998)
    Oxford [u.a.] : International Union of Crystallography (IUCr)
    Acta crystallographica 54 (1998), S. 1491-1493 
    Details
    ISSN: 1600-5759
    Source: Crystallography Journals Online : IUCR Backfile Archive 1948-2001
    Topics: Chemistry and Pharmacology , Geosciences , Physics
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1107/S0108270198007446
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 3
    Electronic Resource
    Electronic Resource
    Hepatitis B virus carriers in the treatment of malignant lymphoma: An epidemiological study in Japan (1997)
    Springer
    Annals of oncology 8 (1997), S. 107-109 
    Details
    ISSN: 1569-8041
    Keywords: chemotherapy ; HBV carrier ; hepatitis B ; malignant lymphoma
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Background: Hepatitis B after the withdrawal of cytotoxicchemotherapy in hepatitis B virus (HBV) carriers is well known and may leadto fatal hepatic failure. We retrospectively analyzed the prevalence of HBVcarriers, the incidence, and the risk factors of hepatitis B in the treatmentof malignant lymphoma. Patients and methods: HBV carriers were defined as patients withpositive HBs-antigen, either with normal or abnormal serum aminotransferaselevel at patient presentation. Questionnaires to the members of the JapanLymphoma Treatment Study Group included general information, details about HBVcarriers, and further information about hepatitis B. Results: Among 1380 patients collected from eight institutions, 45patients (3.26%) were determined to be HBV carriers. Hepatitis Bdeveloped in 17 of the HBV carrying patients (37.8%). Seven of those17 (41.2%) died of hepatic failure. Hepatitis developed at a high ratein patients who were negative for HBe-antigen (50%), and who hadreceived second- or third-generation chemotherapy (63.2%). Conclusion: We confirmed that hepatitis B developed with highfrequency in HBV carriers with malignant lymphoma. Moreover, hepatitis oftenresulted in fatal hepatic failure. It is necessary to prevent the hepatitisB developing in HBV carriers when receiving intensive chemotherapy formalignant lymphoma.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1023/A:1008234807768
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...